Latest News
The Boom in Life Sciences in India
India is emerging as one of the most dynamic life sciences markets in the world. Long recognised for its strength in pharmaceuticals and generics, the country is now experiencing a broader life sciences boom that spans biotechnology, vaccines, medical devices,...
Latest News
Part II – Trade, Capital and the UK Life Sciences Strategy
Henry Li’s BioRoundup is a weekly analytical roundup that tracks where power, capital and science are actually moving in the global life-sciences ecosystem. Rather than simply reporting news headlines, Li curates developments from across deals, policy, industry...
Mapping a Single Neuron
This visualization from the Lichtman Lab and Google Connectomics captures one of the most detailed looks we’ve ever had at a single cortical neuron. What you’re seeing isn’t an artist’s rendering — it’s a true 3D reconstruction built from electron microscopy, stitched...
Windward Bio Strikes $700M Licensing Deal for Qyuns Immunology Bispecific
Swiss biotechnology company Windward Bio has entered into a significant licensing agreement with Chinese biotech Qyuns Therapeutics, securing rights outside China to a clinical stage immunology bispecific antibody known as WIN027, also referred to as QX027N. The...
Manufacturing and Supply Chain Resilience for Advanced Therapies
Manufacturing and supply chain resilience has moved to the forefront of strategic planning across the life sciences industry as advanced therapies place unprecedented strain on existing production models. Cell therapies, gene therapies, mRNA platforms and increasingly...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Part I – Platforms, Pipelines and Incentives in Global Biopharma
Henry Li’s BioRoundup is a weekly analytical roundup that tracks where power, capital and science are actually moving in the global life-sciences ecosystem. Rather than simply reporting news headlines, Li curates developments from across deals, policy, industry...
UK Winter Flu 2025: Current Trends and Vaccine Advice
As the UK enters the heart of the 2025 to 2026 winter respiratory season, influenza flu is emerging as a major public health challenge, with cases rising earlier and more sharply than usual. Health services are already under strain, and experts are urging the public...
Metabolic Myths That Hold you Back
In the age of endless diet tips and health hacks, metabolic health has become one of the most misunderstood topics. People try hard… they cut calories, walk more, sleep less, snack less… yet nothing changes. The problem isn’t effort. It’s misinformation. Metabolic...
Are Mega-Deals Back for Real?
By early Q4 2025, global pharma M&A had already crossed $70B in announced value, driven heavily by a handful of mega-deals, more than 2024, and tracking toward the highest levels since the post-2015 boom. Unlike 2023–24, this wave isn’t driven by small tuck-ins....
AI Drug Discovery Moves from Hype to Measurable Output
Artificial intelligence is increasingly being judged on clinical progress and tangible outcomes, not just models and algorithms. Once a speculative concept, AI-driven drug discovery is now generating real-world data, advancing molecules into human studies, reshaping...
The Science Behind Sleep, Exercise and Hydration Targets
For decades, public health messaging has revolved around simple numerical targets. Get eight hours of sleep. Exercise for 150 minutes a week. Drink eight glasses of water a day. These guidelines are easy to remember and widely promoted, but they also raise an...
Top 5 Global Diseases and Future Outlook for Life Science Innovation
The landscape of global disease continues to evolve, shaped by demographic shifts, environmental pressures, and rapid advances in biomedical innovation. For life science professionals, understanding where the world’s highest-burden diseases stand today, and where...
Investor Trends and Valuation Shifts in the Volatile Biotech Sector
The biotechnology sector is navigating a turbulent market environment in 2025. After earlier highs, many biotech companies have seen steep share-price declines, while investors remain cautious yet selective about which assets to back. As macroeconomic pressures and...
Must-Track Biomarkers
The Numbers That Reveal Your Metabolic Health Today… and Your Risk Tomorrow Most people rely on weight or BMI to judge their health… yet neither tells you how your metabolism is actually working. True metabolic health comes from understanding what’s happening inside...
Gene and RNA Therapies Gain Momentum in Obesity Treatment
The field of obesity treatment is expanding beyond GLP 1 receptor agonists as a growing wave of gene modulating and RNA based therapies emerges. These next generation programmes aim to address fat accumulation, particularly visceral fat and metabolic dysfunction,...
How Neurons Help Cancer Spread
One of the biggest surprises in modern cancer biology is that tumors are wired with nerves—and cancers with more nerve fibers tend to be more aggressive. A new study finally explains why. The Key Finding Neurons actively transfer their mitochondria — the cell’s energy...
Astatine-211: The Alpha-Emitter Gaining Momentum in Targeted Radiotherapy
Astatine, the heaviest halogen and the rarest naturally occurring element, has long been a scientific curiosity. Among its many isotopes, ²¹¹At has emerged over the past decade as a frontrunner in the quest to harness alpha particles for highly targeted radiotherapy....
Part I – Platforms, Pipelines and Incentives in Global Biopharma
Henry Li’s BioRoundup is a weekly analytical roundup that tracks where power, capital and science are actually moving in the global life-sciences ecosystem. Rather than simply reporting news headlines, Li curates developments from across deals, policy, industry...
UK Winter Flu 2025: Current Trends and Vaccine Advice
As the UK enters the heart of the 2025 to 2026 winter respiratory season, influenza flu is emerging as a major public health challenge, with cases rising earlier and more sharply than usual. Health services are already under strain, and experts are urging the public...
Metabolic Myths That Hold you Back
In the age of endless diet tips and health hacks, metabolic health has become one of the most misunderstood topics. People try hard… they cut calories, walk more, sleep less, snack less… yet nothing changes. The problem isn’t effort. It’s misinformation. Metabolic...
Are Mega-Deals Back for Real?
By early Q4 2025, global pharma M&A had already crossed $70B in announced value, driven heavily by a handful of mega-deals, more than 2024, and tracking toward the highest levels since the post-2015 boom. Unlike 2023–24, this wave isn’t driven by small tuck-ins....
AI Drug Discovery Moves from Hype to Measurable Output
Artificial intelligence is increasingly being judged on clinical progress and tangible outcomes, not just models and algorithms. Once a speculative concept, AI-driven drug discovery is now generating real-world data, advancing molecules into human studies, reshaping...
The Science Behind Sleep, Exercise and Hydration Targets
For decades, public health messaging has revolved around simple numerical targets. Get eight hours of sleep. Exercise for 150 minutes a week. Drink eight glasses of water a day. These guidelines are easy to remember and widely promoted, but they also raise an...
Top 5 Global Diseases and Future Outlook for Life Science Innovation
The landscape of global disease continues to evolve, shaped by demographic shifts, environmental pressures, and rapid advances in biomedical innovation. For life science professionals, understanding where the world’s highest-burden diseases stand today, and where...
Investor Trends and Valuation Shifts in the Volatile Biotech Sector
The biotechnology sector is navigating a turbulent market environment in 2025. After earlier highs, many biotech companies have seen steep share-price declines, while investors remain cautious yet selective about which assets to back. As macroeconomic pressures and...
Must-Track Biomarkers
The Numbers That Reveal Your Metabolic Health Today… and Your Risk Tomorrow Most people rely on weight or BMI to judge their health… yet neither tells you how your metabolism is actually working. True metabolic health comes from understanding what’s happening inside...
Gene and RNA Therapies Gain Momentum in Obesity Treatment
The field of obesity treatment is expanding beyond GLP 1 receptor agonists as a growing wave of gene modulating and RNA based therapies emerges. These next generation programmes aim to address fat accumulation, particularly visceral fat and metabolic dysfunction,...
How Neurons Help Cancer Spread
One of the biggest surprises in modern cancer biology is that tumors are wired with nerves—and cancers with more nerve fibers tend to be more aggressive. A new study finally explains why. The Key Finding Neurons actively transfer their mitochondria — the cell’s energy...
Astatine-211: The Alpha-Emitter Gaining Momentum in Targeted Radiotherapy
Astatine, the heaviest halogen and the rarest naturally occurring element, has long been a scientific curiosity. Among its many isotopes, ²¹¹At has emerged over the past decade as a frontrunner in the quest to harness alpha particles for highly targeted radiotherapy....
Featured Articles
Further News
Life Science Development in Singapore: A Rising Global Powerhouse
Singapore has rapidly transformed into one of the world’s most advanced and influential life science hubs. Over the past two decades, the city-state has combined strategic investment, world-class infrastructure, and a thriving innovation ecosystem to position itself...
Life Science Daily News: Join the Community
A Community-Driven Hub for Life Sciences News and Discovery In an era of rapid scientific progress and near-constant breakthroughs, having a reliable, inclusive platform to share and explore life-sciences news is more important than ever. Life Science Daily News...
Halozyme Granted Injunction Against Merck in Keytruda Patent Case
A German court has granted Halozyme a preliminary injunction that halts the sale of the subcutaneous version of Keytruda in Germany, marking a significant legal win in the companies’ high stakes patent dispute. The decision could complicate Merck’s plans for the...
Pharma 5.0: The Future of Human-Centric, Intelligent, Sustainable Medicine
As the pharmaceutical industry undergoes rapid transformation, a new paradigm is taking shape. Known as Pharma 5.0, it represents more than an upgrade in technology, it is a fundamental shift toward human-centric innovation, sustainable manufacturing, and intelligent...
Pharvaris Announces Positive Phase 3 Results for Deucrictibant
Pharvaris Announces Positive Phase 3 Results for Deucrictibant as On Demand HAE Treatment Pharvaris has announced positive topline data from its global Phase 3 RAPIDe 3 study, confirming that the oral bradykinin B2 receptor antagonist deucrictibant shows strong...
AI & Cloud Enabled R&D and Clinical Operations Surge in Life Sciences
Digital transformation is accelerating across the life sciences sector as more organisations adopt AI driven platforms and cloud computing to speed up drug discovery, streamline clinical trials and optimise operations. A recent industry overview from BioSpace...
Autolus CAR-T Offers Hope to Adults with Aggressive Blood Cancer
The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending a novel, next-generation chimeric antigen receptor T-cell (CAR-T) therapy for use in the National Health Service (NHS). This landmark decision is set to...
Otsuka Wins Approval for Novel Rare Kidney Drug
Otsuka Gains Approval for First of Its Kind Treatment Against Rare Kidney Disease In a significant milestone for kidney disease care, Otsuka Pharmaceutical has received accelerated approval from the US Food and Drug Administration for a new therapy for Immunoglobulin...
US and UK Agree Zero Tariffs Deal on Pharmaceuticals
US and UK Agree Zero Tariffs Deal on Pharmaceuticals: What It Means for Patients, Innovation and Global Pharma Trade The United States and the United Kingdom have reached a landmark trade agreement that eliminates tariffs on UK-origin pharmaceuticals, active...
Hot Topic to Watch in China Life Sciences: Data Exclusivity & IP Reforms
China’s life sciences sector is poised for a potential regulatory shake-up this week, as stakeholders await clarity on data exclusivity and intellectual property (IP) protection reforms. Earlier this year, the National Medical Products Administration (NMPA) released a...
A Milestone in Rare Disease Genomics
Why popEVE Matters Interpreting missense variants has long been one of the most persistent challenges in clinical genetics. These single–amino-acid substitutions can subtly alter protein structure or function, yet their effects are often context-dependent and...
Brain Cell Communication at the Molecular Level
Brain Cell Communication at the Molecular Level Neural communication isn’t abstract, it’s a sequence of tightly regulated biophysical events. Ion gradients shift, channels open and close with millisecond precision, calcium signals trigger chemical release, and...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Welcome to Life Science Daily News
Your Gateway to Discovery, Innovation, and Global Scientific Voices In a world where breakthroughs happen every day and scientific understanding is accelerating faster than ever before, Life Science Daily News stands as a vibrant hub for curious minds, passionate...
New Hope for Patients with Hereditary Hemorrhagic Telangiectasia
Engasertib Trial Offers New Hope for Patients with Hereditary Hemorrhagic Telangiectasia A recent clinical study has delivered encouraging results for people living with hereditary hemorrhagic telangiectasia, a rare genetic vascular disorder that causes chronic and...
ALS- Clinical Signals of a “Synaptic Regenerative” Approach!
Pharmaceutical approaches to ALS remain sparse and "hard-to-develop". Riluzole (approved 1995) and edaravone (IV in 2017, oral in 2022) only offer modest benefits. More recently, Biogen's Qalsody (tofersen) was approved for SOD1-mutant ALS. But a new wave of new...
Decision Frameworks in Pharma
Decision Frameworks in Pharma: From RAVE and DICE to Lilly’s Truth-Seeking Machine What Works, What Kills What, and Why It Matters In pharmaceutical R&D, where billions ride on the flip of a biological coin, decision frameworks aren’t just nice-to-haves - they’re...
Follow the Science? It Would Rather Follow a Leader… (2025 Update)
Eight years on from the first version of this article, “follow the science” is still the industry’s favourite comfort blanket. It sounds noble, unassailable, the kind of thing you put on a lab-wall poster next to a photo of Rosalind Franklin. (Following the X...
Durvalumab approved in the US
Durvalumab approved in the US as first & only perioperative immunotherapy for patients with early gastric & gastroesophageal cancers! The FDA approved Durvalumab (Imfinzi) in combination with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)...
Redefining Drug Safety: Global Regulators Push for AI and 3D Tissues
For decades, the laboratory rat has been the quintessential symbol of biomedical research. Yet, as 2025 draws to a close, a profound shift is reshaping the life sciences landscape. Global regulatory bodies are no longer merely encouraging alternatives to animal...
Novartis to Acquire Avidity in $12B RNA Therapy Deal
The biotech M&A boom shows no signs of slowing. Novartis has struck a definitive agreement to acquire Avidity Biosciences for US$12 billion in cash, marking one of the most consequential acquisitions in the RNA therapy space in recent years. The deal significantly...
Ground-Breaking Gene Therapy for Hunter Syndrome
Miraculous Progress for 3-Year-Old After Ground-Breaking Gene Therapy for Hunter Syndrome A three-year-old boy, Oliver Chu, has astounded doctors after becoming the first person in the world with Hunter syndrome also called MPS II to receive a pioneering gene therapy....
UK Drug Pricing Pressure Threatens Pharma Investment and Competitiveness
The row over drug pricing in the United Kingdom has escalated into a defining test for the government’s life sciences strategy. In 2025 tensions between Whitehall and major pharmaceutical companies have hardened, with a series of high-profile investment pauses and...
AstraZeneca and Sun Pharma Join Forces in India
AstraZeneca and Sun Pharma Join Forces to Expand Access to Hyperkalaemia Treatment in India In a major development for renal and cardiac care in India, AstraZeneca Pharma India and Sun Pharmaceutical Industries have announced a strategic co-marketing partnership to...
J&J Acquires Halda Therapeutics to Boost Oncology Pipeline
Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion in cash, a transaction announced on 17 November 2025 and expected to close in the coming months, subject to customary regulatory approvals. Halda’s Novel RIPTAC Modality Halda...
Welcome to Life Science Daily News
Your Gateway to Discovery, Innovation, and Global Scientific Voices In a world where breakthroughs happen every day and scientific understanding is accelerating faster than ever before, Life Science Daily News stands as a vibrant hub for curious minds, passionate...
New Hope for Patients with Hereditary Hemorrhagic Telangiectasia
Engasertib Trial Offers New Hope for Patients with Hereditary Hemorrhagic Telangiectasia A recent clinical study has delivered encouraging results for people living with hereditary hemorrhagic telangiectasia, a rare genetic vascular disorder that causes chronic and...
ALS- Clinical Signals of a “Synaptic Regenerative” Approach!
Pharmaceutical approaches to ALS remain sparse and "hard-to-develop". Riluzole (approved 1995) and edaravone (IV in 2017, oral in 2022) only offer modest benefits. More recently, Biogen's Qalsody (tofersen) was approved for SOD1-mutant ALS. But a new wave of new...
Decision Frameworks in Pharma
Decision Frameworks in Pharma: From RAVE and DICE to Lilly’s Truth-Seeking Machine What Works, What Kills What, and Why It Matters In pharmaceutical R&D, where billions ride on the flip of a biological coin, decision frameworks aren’t just nice-to-haves - they’re...
Follow the Science? It Would Rather Follow a Leader… (2025 Update)
Eight years on from the first version of this article, “follow the science” is still the industry’s favourite comfort blanket. It sounds noble, unassailable, the kind of thing you put on a lab-wall poster next to a photo of Rosalind Franklin. (Following the X...
Durvalumab approved in the US
Durvalumab approved in the US as first & only perioperative immunotherapy for patients with early gastric & gastroesophageal cancers! The FDA approved Durvalumab (Imfinzi) in combination with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)...
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.